RT Journal Article
SR Electronic
T1 Design and validation of HIV peptide pools for detection of HIV-specific CD4<sup>+</sup> and CD8<sup>+</sup> T cells
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.29.22274468
DO 10.1101/2022.04.29.22274468
A1 Alkolla, Rita
A1 Grifoni, Alba
A1 Crotty, Shane
A1 Sette, Alessandro
A1 Gianella, Sara
A1 Dan, Jennifer
YR 2022
UL http://medrxiv.org/content/early/2022/05/01/2022.04.29.22274468.abstract
AB Reagents to monitor T cell responses to the entire HIV genome, based on well characterized epitopes, are missing. Evaluation of HIV-specific T cell responses is of importance to study natural infection, and therapeutic and vaccine interventions. Experimentally derived CD4+ and CD8+ HIV epitopes from the HIV molecular immunology database were developed into Class I and Class II HIV megapools (MPs). We assessed HIV responses in persons with HIV pre combined antiretroviral therapy (cART) (n=17) and post-cART (n=18) and compared these responses to 15 controls without HIV (matched by sex, age, and ethnicity). Using the Activation Induced Marker (AIM) assay, we quantified HIV-specific total CD4+, memory CD4+, circulating T follicular helper, total CD8+ and memory CD8+ T cells. We also compared the Class I and Class II HIV MPs to commercially available HIV gag peptide pools. Overall, HIV Class II MP detected HIV-specific CD4+ T cells in 21/35 (60%) HIV positive samples and 0/15 HIV negative samples. HIV Class I MP detected an HIV-specific CD8+ T cells in 17/35 (48.6%) HIV positive samples and 0/15 HIV negative samples. Our innovative HIV MPs are reflective of the entire HIV genome, and its performance is comparable to other commercially available peptide pools. Here, we detected HIV-specific CD4+ and CD8+ T cell responses in people on and off cART, but not in people without HIV.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study has been funded by the NIH NIAID contract Nr. 75N93019C00065 to A.S., R24 AI106039 (Primary Infection Resource Consortium) to Susan Little, R01 AI47821 to S.G., P30 AI036214 (San Diego Center for AIDS Research), and K08 AI135078 to J.D. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UCSD IRB Project #140093X LJI IRB VD-057-0217I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableData is available upon request for FACS files. All relevant data are within the manuscript.